Stockreport

Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Histogen Inc.  (HSTO) 
PDF SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO),  a clinical-stage therapeutics company focused on developing potential first-in-class resto [Read more]